MSD and MD Anderson reach strategic cooperation in tumor immunology
-
Last Update: 2015-08-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Biovalley, August 14, 2015 Merck & Co, the US pharmaceutical giant, recently entered into a strategic clinical research cooperation with MD Anderson Cancer Center, the largest cancer treatment center in the United States, to investigate the combination of other drugs (such as chemotherapy, radiotherapy and/ Or new antitumor drugs) for solid tumors According to the terms of the agreement, the three-year clinical cooperation will cover the following tumor types: gastroesophageal adenocarcinoma, pancreatic cancer and liver cancer The first studies plan to start patient recruitment later this year The aim of this cooperation is to determine the best combination of keytruda by exploring promising new alternative therapies, so that keytruda can play a better anti-tumor effect in the treatment of these types of tumors The new cooperation with MD Anderson is part of the assessment of keytruda's strategy for the treatment of multiple types of tumors and combination therapy, which will speed up the pace of exploration and help to bring new treatment options to patients, mosadong said Moreover, MD Anderson is a key contributor to the early experimental exploration of keytruda in the treatment of various types of tumors The past research cooperation between the two sides has played a key role in promoting keytruda to obtain FDA approval for the treatment of unresectable or metastatic melanoma Keytruda belongs to PD-1 / PD-L1 immunotherapy, which aims to use the human body's own immune system to resist cancer, and block the PD-1 / PD-L1 signal pathway to make cancer cells die In clinical trials, keytruda has a strong effect on many types of tumors The competition in the field of PD-1 / PD-L1 is very fierce, with a peak market value of US $35 billion The leading players include Bristol Myers Squibb, MSD, Roche and AstraZeneca At present, major giants are rapidly promoting large-scale clinical projects of their own drugs, exploring the clinical potential of single drug and combination therapy for multiple types of tumors.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.